Skip to content
OpenCapital
Get started

Agios Pharmaceuticals AGIO Allowance for Doubtful Accounts Receivable (Current)

Allowance for Doubtful Accounts Receivable (Current) at other companies

Precigen logo
PrecigenPGEN
$0—

Other financials

Income statement

See full
Revenue$20.7M+138%
Gross profit$19.4M+154%
Operating income-$110.0M-3.2%
Net income-$99.1M-11.0%
EPS (diluted)-$1.69-9.0%

Balance sheet

See full
Cash & equivalents$113.6M+43.9%
Total debt$35.7M-32.5%
Total equity$1.1B-24.4%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow-$118.9M-6.7%
CapEx$769.0K+0.4%
Free cash flow-$119.7M-6.6%

Valuation

See full
Market cap$2.16B+18.1%

Profitability

See full
Gross margin90%+2.5pp
Operating margin-720%-204pp
Net margin-639.8%—
FCF margin-582.5%-185pp

Returns & leverage

See full
Return on equity-32.8%—
Debt / equity0×0.0×
Current ratio14.2×-4.3×

Where this comes from

Reported directly by Agios Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent.

The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Agios Pharmaceuticals's allowance for doubtful accounts receivable (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Agios Pharmaceuticals's allowance for doubtful accounts receivable (current)?
Agios Pharmaceuticals (AGIO) reported allowance for doubtful accounts receivable (current) of $208K in Q1 2026.
How has Agios Pharmaceuticals's allowance for doubtful accounts receivable (current) changed year-over-year?
Agios Pharmaceuticals's allowance for doubtful accounts receivable (current) increased by 166.7% year-over-year, from $78K to $208K.
What does allowance for doubtful accounts receivable (current) mean?
This is the valuation allowance for current receivables that are considered uncollectible due to disputes, bankruptcy, or other non-payment issues. It serves as a buffer against potential losses from customer defaults. It is a critical indicator of the health of the company's accounts receivable portfolio.